Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

SOUTH SAN FRANCISCO, Calif., March 11 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule therapeutics, today reported financial results for the quarter and fiscal year ended December 31, 2007.

Total revenue for the fourth quarter of 2007 was $2.0 million, with a net loss of $8.8 million. Total revenue for the year ended December 31, 2007 was $9.7 million, with a net loss of $38.8 million. As of December 31, 2007, cash, cash equivalents and marketable securities totaled $47.7 million, and debt totaled $2.3 million. Net cash used in operating activities in 2007 was $34.5 million.

Recent Highlights

-- This week at the 39th Annual Meeting on Women's Cancer hosted by the Society for Gynecologic Oncology in Tampa, Florida, Sunesis presented positive interim results from the company's ongoing Phase 2 clinical trial of SNS-595, a novel naphthyridine analog, in advanced platinum-resistant ovarian cancer patients.
-- Sixty-five women have been enrolled and treated with single-agent

SNS-595 at a dose of 48 mg/m2 administered once every three weeks,

with the majority of these women having been enrolled since October.

Forty-five women have sufficient follow up to yield useful safety

results and 35 are evaluable for best response using GOG-RECIST

criteria.

-- In this trial, SNS-595 has demonstrated disease control (defined as

stable disease, partial response or complete response), with 31 of

35 of evaluable patients having best responses of stable disease or

better. Of
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... December 18, 2014 With only 2 ... special on Sartorius Biohit products . The product ... pipettes, Picus Electronic Pipette Trade-in Program, and free pipette ... Safety officers around the world. They are ideal for ... features include:, ,     Full volume range of ...
(Date:12/19/2014)... Egenix, Inc. is pleased to announce that Lionel Goldfrank ... succeed Donald Fresne ; Mr. Fresne has also resigned ... of the Board.  In recognition of the many contributions and ... twenty years, the Board designated Mr. Fresne as Chairman Emeritus. ... Search Committee to find a suitable replacement with Biotech industry ...
(Date:12/19/2014)... -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company ... announced the results of its annual general meeting of ... year in Relmada,s history and it set the stage ... Sergio Traversa , chief executive officer of Relmada. "Over ... human resource and clinical development objectives that position Relmada ...
(Date:12/17/2014)... December 17, 2014 Based on ... overall surgical imaging market is dominated by four ... surgical imaging market. These players include GE Healthcare ... Imaging (Germany). , Full Report Copy at ... GE Healthcare can be attributed to its strong ...
Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4
... Technology to Find a Faster, More Accurate ... 1 ChemImage, ( www.chemimage.com ) today ... Breath, LLC ( www.nextbreath.net ), a leading ... ChemImage,s Raman Chemical Imaging for bioequivalence applications ...
... PETACH TIKVA, Israel, April 1 NexGen Biofuels,Ltd. ... a non-binding,Letter of Intent with World Venture Management ... ("WVM" ) and Mac Bioventures, Inc. The transaction,includes ... relating to its Real,Estate acquisitions and asset management ...
... 1 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX:SBS), ... and oils in plant seeds, provides an ... insulin program. In December 2008, SemBioSys announced ... to license rights to SemBioSys, proprietary plant-produced ...
Cached Biology Technology:ChemImage and Next Breath Structure Partnership to Validate Bioequivalence Testing for Nasal Spray Suspensions 2ChemImage and Next Breath Structure Partnership to Validate Bioequivalence Testing for Nasal Spray Suspensions 3NexGen Biofuels Ltd Signs Letter of Intent for the Purchase of World Venture Management, Inc. Assets and the Sale of its Current Business 2SemBioSys provides update on insulin program 2SemBioSys provides update on insulin program 3
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a leader ... PerformTek biometric technology to industry leaders such as Intel, ... clinically validated, biometric wearable products. These products will be ... Las Vegas . ... accurate, flexible and robust – with the clinical data ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the ... 2015-2019" report to their offering. ... is the adoption of multimodal biometric systems. Multimodal ... an individual for verification and identification purposes. This ...
(Date:12/10/2014)... WINSTON-SALEM, N.C. , Dec. 9, 2014  Wake Forest ... medical education building for its School of Medicine. Funding ... a larger capital campaign that will be publicly launched ... will be located in the former 60 series R.J. ... Forest Innovation Quarter. Construction will begin immediately with plans ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... Frontiers, one of the world,s fastest-growing Open Access publishers ... announces the launch of a new journal, Frontiers ... Health will publish high quality, rigorously peer-reviewed articles ... the entire research spectrum of Public Health. On ...
... Researchers at the UAB,s Institute of Environmental Science and ... have analysed the potential of different species of microalgae ... and the quantity of lipids per cell (essential for ... type of marine algae that has received little attention ...
... A Kansas State University research team has found ... nitrogen availability in many ecosystems has remained steady ... in the journal Nature . "People ... times because it,s a major pollutant," said Kendra ...
Cached Biology News:Frontiers announces launch of new open-access journal, Frontiers in Public Health 2Microalgae could be a profitable source of biodiesel 2Global nitrogen availability consistent for past 500 years, linked to carbon levels 2Global nitrogen availability consistent for past 500 years, linked to carbon levels 3
... Zyagen tissue microarrays are derived from Paraffin ... rigorous quality control procedures to ensure the ... manually assembled in one block, sectioned at ... on coated slides. Sections are large (3-5mm ...
... Zyagen tissue microarrays are derived from Paraffin ... rigorous quality control procedures to ensure the ... manually assembled in one block, sectioned at ... on coated slides. Sections are large (3-5mm ...
... PCR detection system uses a fixed array ... and a photomultiplier tube for fluorescence detection ... on an DNA Engine thermal cycler base, ... item includes the thermal cycler, 96-well sample ...
... The MyiQ detection system is used ... I, FAM, VIC, TET, or JOE fluorophores ... simultaneous collection of fluorescence data from 96 ... quantitation, and customizable end-point analysis. The system ...
Biology Products: